Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing

Did You Buy This Biotech Buyout Stock?

In the March 26 Private Briefing report "Double Your Money on This Tiny Firm's Super Bug Drug," we told readers that biotech Trius Therapeutics Inc. (Nasdaq: TSRX) was poised for a 100% pop.

And a 100% pop is just what you got - and then some.

It always feels great when one of our predictions works out this way.

To continue reading, please click here...

Leave a Reply

Your email address will not be published. Required fields are marked *

Some HTML is OK